Editor’s Note
**Editor’s Note:** Hugel sets an ambitious 9% market share target for India’s aesthetic market this year, leveraging the country’s untapped potential in botulinum toxin treatments.
Hugel, which has been expanding its botulinum toxin business globally, has entered the Indian market. India is seeing steady growth in aesthetic medical procedures, but the proportion of botulinum toxin treatments remains low, making it a market with significant growth potential.
According to Hugel on the 22nd, the company participated in the ‘Global Aesthetic Summit (GAS)’ held from the 19th to the 21st at the Taj Holiday Village in Goa, India, officially announcing the local launch of its botulinum toxin product ‘Letibo’.
India’s demand for aesthetic procedures is rising due to the expansion of the middle class and increasing interest in medical aesthetics. Market research firm Grand View Research estimated the Indian botulinum toxin market’s revenue at approximately $307.3 million (about 425 billion KRW) last year, projecting it to grow to around $723.8 million (about 1 trillion KRW) by 2033. Hugel aims to secure a 9% market share in the Indian aesthetic market within this year.
Meanwhile, Hugel is using this local event not only for product promotion but also as an opportunity to expand contact with key medical professionals. Until the 24th, the company is conducting launch events and hands-on workshops with local distributors to introduce Letibo’s product features and treatment information, aiming to solidify its presence in the Asia-Pacific region using India as a foothold.
